BioPharma Dive November 20, 2024
Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for lung cancer and obesity, adding to collaborations it formed with other Flagship startups earlier this year.
Dive Brief:
- Pfizer will work with two more startups incubated by Flagship Pioneering, which on Wednesday announced that Montai Therapeutics and Ampersand Biomedicines would hunt for drug candidates under an existing collaboration with the pharmaceutical giant.
- Montai aims to unearth new small molecule drugs for lung cancer, while Ampersand will help the pharma discover biologics for obesity. Flagship didn’t reveal financial terms for either deal, though a spokesperson said Pfizer will split R&D costs and has an option to license a program.
- Both deals are products of an alliance Pfizer...
Today's Sponsors
Today's Sponsor